SciSparc Ltd. (SPRC)
SPRC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1611746/000121390026049322/0001213900-26-049322-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SPRC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | Not reported by the screener |
| SEC CIK | 0001611746 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Israel |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $856K |
| Net income | -$12.2M |
| Operating income | -$8.4M |
| Net margin | -1422.8% |
| Operating margin | -978.3% |
| Revenue growth | -34.5% |
| Cash | $4.6M |
| Total assets | $7.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about our ability to continue as a going concern." | 20-F 2026-04-29 |
| Cash and burn | $4.6M cash; operating cash flow -$1.0M a quarter. | Report 2025-12-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2025-12-31 |
| Reverse splits, 3 years | 2; latest 1-for-9 on 2026-03-04 | Source 2026-03-04 |
| Shelf and offerings, 12 months | 3 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-01-14 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Brightman Almagor Zohar & Co., Tel Aviv, Israel | PCAOB Form AP 2026-06-03 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $5K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $856K | -$12.2M | -$4.1M | $4.6M | $356K | $856K | 20-F 2026-04-29 |
| FY 2024 2024-12-31 | $1.3M | -$6.3M | -$5.1M | $1.5M | No debt tags | $1.3M | 20-F 2025-04-24 |
| FY 2023 2023-12-31 | $2.9M | -$5.1M | -$5.9M | $2.1M | No debt tags | $2.9M | 20-F 2025-04-24 |
| FY 2022 2022-12-31 | $1.3M | -$2.6M | -$7.9M | $3.6M | No debt tags | $1.3M | 20-F 2025-04-24 |
| FY 2021 2021-12-31 | Not filed | -$5.8M | -$5.1M | $6.9M | No debt tags | Needs four quarters | 20-F/A 2024-05-02 |
| FY 2020 2020-12-31 | Not filed | -$3.5M | -$4.3M | $7.8M | No debt tags | Needs four quarters | 20-F 2021-03-30 |
| FY 2019 2019-12-31 | Not filed | -$4.7M | -$4.7M | $870K | No debt tags | Needs four quarters | 20-F 2021-03-30 |
| FY 2018 2018-12-31 | Not filed | -$8.9M | -$7.1M | $1.5M | No debt tags | Needs four quarters | 20-F 2021-03-30 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | F-3 | 2026-11-09 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-04-29 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 610 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -15.8% |
| 1 month | -91.0% |
| 3 months | -94.7% |
| Year to date | -97.1% |
| 1 year | -98.5% |
| From 52-week high | -98.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OGEN | Oragenics Inc. | $0.1980 | -1.49% | $893K |
| MTNB | Matinas Biopharma Holdings Inc. | $0.9270 | +3.00% | $908K |
| GOVX | GeoVax Labs Inc. | $2.02 | +18.48% | $1.1M |
| BDRX | Biodexa Pharmaceuticals plc American Depositary Shs | $2.24 | -6.28% | $1.2M |
| LABT | Lakewood-Amedex Biotherapeutics Inc. | $0.2194 | -22.31% | $520K |
| ELAB | PMGC Holdings Inc. | $1.66 | +5.06% | $1.3M |
| KAPA | Kairos Pharma Ltd. | $0.4069 | -10.30% | $1.4M |
| APVO | Aptevo Therapeutics Inc. | $0.5486 | -7.66% | $1.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier